Bar-Am Amiram, Gamzu Ronni, Levin Ishai, Fainaru Ofer, Niv Jakov, Almog Benny
Cervical Pathology Unit, Department of Obstetrics and Gynecology, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel 64239.
Gynecol Oncol. 2003 Oct;91(1):149-53. doi: 10.1016/s0090-8258(03)00435-9.
The goal of this study was to evaluate the clinical implications of integrating human papillomavirus (HPV) testing into a long-term follow-up and management protocol for women postconization for high-grade cervical intraepithelial neoplasia (CIN2-3).
Sixty-seven women were followed-up by Pap smears and HPV type and load testing (mean follow-up, 63 months; range, 50-72). Patients with persistent abnormal cytology on two consecutive smears and those with positive HPV test results (whatever their cytologic findings) were referred for colposcopy-directed biopsy. Patients histologically diagnosed with CIN2-3 and those with high-load HPV (whatever their histologic findings) underwent repeat conization or hysterectomy for residual disease.
At follow-up, 29 (43.2%) women had positive cytology or positive HPV results and were referred for colposcopy. Eleven (37.9%) had high-grade cervical intraepithelial neoplasia or high-load HPV results and were further treated by reconization/hysterectomy. The respective positive predictive values of high-load HPV and low-grade squamous intraepithelial lesions were 100 and 60% for any CIN and 90 and 15% for CIN2-3. Only five of nine cases with a final diagnosis of CIN2-3 were originally identified by cytology: the other four were detected only by parallel evaluation by HPV testing. High-load HPV results with normal cytology or low-grade lesions harbored an 80% risk for CIN2-3.
Adding HPV load assessment to the follow-up protocol of women postconization due to CIN2-3 lesions could help detect high-grade residual disease among low-grade lesions and normal cytology cases while concomitantly and safely bestowing the advantage of lowering the rates of colposcopic referrals and surgical procedures.
本研究的目的是评估将人乳头瘤病毒(HPV)检测纳入高级别宫颈上皮内瘤变(CIN2-3)锥切术后女性的长期随访和管理方案的临床意义。
对67名女性进行巴氏涂片以及HPV分型和载量检测随访(平均随访63个月;范围50-72个月)。连续两次涂片细胞学检查持续异常的患者以及HPV检测结果呈阳性的患者(无论其细胞学检查结果如何)均被转诊接受阴道镜引导下活检。组织学诊断为CIN2-3的患者以及HPV高载量患者(无论其组织学检查结果如何)因残留疾病接受再次锥切术或子宫切除术。
随访时,29名(43.2%)女性细胞学检查呈阳性或HPV结果呈阳性,并被转诊接受阴道镜检查。11名(37.9%)患有高级别宫颈上皮内瘤变或HPV高载量结果,进一步接受再次锥切术/子宫切除术治疗。对于任何CIN,高载量HPV和低级别鳞状上皮内病变的阳性预测值分别为100%和60%,对于CIN2-3则分别为90%和15%。最终诊断为CIN2-3的9例病例中,只有5例最初通过细胞学检查发现:另外4例仅通过HPV检测并行评估发现。细胞学检查正常或病变为低级别但HPV高载量结果者发生CIN2-3的风险为80%。
在因CIN2-3病变接受锥切术的女性随访方案中增加HPV载量评估,有助于在低级别病变和细胞学检查正常的病例中检测出高级别残留疾病,同时安全地降低阴道镜转诊率和手术率。